Gilead Sciences

Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
CP Wire
Gilead Sciences
NASH
selonsertib
GS-9674
GS-0976
Flag link:
Medicare sets outpatient rate for Yescarta reimbursement
Medicare sets outpatient rate for Yescarta reimbursement
Reuters
Medicare
Yescarta
reimbursement
Gilead Sciences
Flag link:
Which Big Pharma CEOs Least Deserved Their Big Pay Increases?
Which Big Pharma CEOs Least Deserved Their Big Pay Increases?
Motley Fool
Big Pharma
Pharma CEOs
executive pay
AbbVie
Bristol-Myers Squibb
Gilead Sciences
JNJ
Pfizer
Flag link:
Gilead: Did Biktarvy Kill The Sell Thesis?
Gilead: Did Biktarvy Kill The Sell Thesis?
Seeking Alpha
Gilead Sciences
Biktarvy
HIV
Kite Pharma
Flag link:
Revenue down? No worries for Gilead CEO Milligan as compensation swells to $15.4M
Revenue down? No worries for Gilead CEO Milligan as compensation swells to $15.4M
Endpoints
Gilead Sciences
Pharma CEOs
John Milligan
executive pay
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Gilead Sciences' $14 Billion-Per-Year Threat
Gilead Sciences' $14 Billion-Per-Year Threat
Motley Fool
Gilead Sciences
GS-9620
GS-9722
HIV
Flag link:
Is Gilead Sciences Trying to Put Itself Out of Business?
Is Gilead Sciences Trying to Put Itself Out of Business?
Motley Fool
Gilead Sciences
hepatitis C
HIV
GS-9620
PGT121
Flag link:
[video]How Pricing Can Be Vital to a Drugmaker's Profitability
[video]How Pricing Can Be Vital to a Drugmaker's Profitability
Motley Fool
drug pricing
Gilead Sciences
AbbVie
hepatitis C
Flag link:
Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys
Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys
Endpoints
HIV
Gilead Sciences
R&D
Flag link:
Gilead Sciences' History Points to Future Success
Gilead Sciences' History Points to Future Success
Motley Fool
Gilead Sciences
hepatitis C
NASH
Flag link:
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
Fierce Pharma
drug launches
hepatitis C
Ibrance
Tecfidera
Biogen
Pfizer
Gilead Sciences
Flag link:
Gilead Sciences: The Oncology Company?
Gilead Sciences: The Oncology Company?
Motley Fool
Gilead Sciences
oncology
Kite Pharma
Cell Design Labs
Sangamo Therapeutics
Flag link:
Gilead loses its head of commercial ops as it takes on daunting sales challenges
Gilead loses its head of commercial ops as it takes on daunting sales challenges
Fierce Pharma
Gilead Sciences
restructuring
Flag link:
Treatment Debates Won’t Slow Down Biotechs
Treatment Debates Won’t Slow Down Biotechs
Barron's
biotech
Gilead Sciences
CAR-T
Juno Therapeutics
Bellicum
Flag link:
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Xconomy
cell therapy
Gilead Sciences
Sangama
CAR-T
gene editing
Flag link:
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
Flag link:
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Biopharma Dive
Gilead Sciences
Merck
patents
Sovaldi
Harvoni
hepatitis C
Idenix
Flag link:
5 Drugs That Are Critical for Gilead Sciences' Future
5 Drugs That Are Critical for Gilead Sciences' Future
Motley Fool
Gilead Sciences
Biktarvy
Yescarta
selonsertib
filgotinib
Epclusa
Flag link:

Pages